ESR1 and breast carcinoma: Among which, TNBC, account for about 15% of all breast cancer patients, is a malignant tumor that characterized by pathological examination showing that estrogen receptor (ER), progesterone receptor (progesterone receptor, PR) and human epidermal growth factor receptor 2 (human 2) are negative, and is considered to be an independent clinical pathological type [8, 9].